• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Two Vaccines Against RSV in Older Adults Approved One Month Apart: It Happened in 2023

News
Slideshow

The seasonal respiratory syncytial virus, which claims between 6000 and 10 000 older adult lives each year, will now face significant barriers to spread in this vulnerable population the US.

The short slide show that follows provides snapshots of the headline news stories posted on Patient Care® in 2023 that traced the clinical trials and approval process for GKS's RSVPreF3 (Arexvy) and Pfizer's RSVPreF (Abrysvo).


Related Content
© 2024 MJH Life Sciences

All rights reserved.